Siemens and Exyte to Deliver Integrated Solutions for Fast-Track Construction of Smart Biotech Facilities

By Janice Abel

Acquisition or Partnership

Siemens, a global leader in process automation, and Exyte, a leader in the design and delivery of biopharmaceutical manufacturing facilities, join forces to offer end-to-end solutions for the biopharmaceutical industry by combining the digitalization expertise of Siemens with the innovation boost from Exyte.

Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities.  Siemens and Exyte are committed to tackle those challenges.  Together, they offer standardized, turnkey solutions compliant with cGMP (current Good Manufacturing Practice) and GAMP (Good Automated Manufacturing Practice) to biotechnology manufacturers as well as cell and gene therapy manufacturers.

Currently, the first buildings with Siemens’ technology and ExyCell modules are being designed for cell and gene therapy manufacturing and biologicals production in China and Europe.


Engage with ARC Advisory Group